α-glucosidase inhibitors as host-directed antiviral agents with potential for the treatment of COVID-19.
Biochem Soc Trans
; 48(3): 1287-1295, 2020 Jun 30.
Article
in English
| MEDLINE | ID: covidwho-592506
ABSTRACT
The ongoing COVID-19 pandemic, caused by SARS-CoV-2, has pushed the health systems of many countries to breaking point and precipitated social distancing measures that have crippled economic activities across the globe. A return to normality is unlikely until effective therapeutics and a vaccine are available. The immediacy of this problem suggests that drug strategies should focus on repurposing approved drugs or late-stage clinical candidates, as these have the shortest path to use in the clinic. Here, we review and discuss the role of host cell N-glycosylation pathways to virus replication and the drugs available to disrupt these pathways. In particular, we make a case for evaluation of the well-tolerated drugs miglitol, celgosivir and especially miglustat for the treatment of COVID-19.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pneumonia, Viral
/
Coronavirus Infections
/
Drug Repositioning
/
Glycoside Hydrolase Inhibitors
/
Betacoronavirus
Type of study:
Experimental Studies
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Language:
English
Journal:
Biochem Soc Trans
Year:
2020
Document Type:
Article
Affiliation country:
Bst20200505
Similar
MEDLINE
...
LILACS
LIS